Injexate (Methotrexate)

Methotrexate works by blocking the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption hampers the synthesis of nucleotides needed for DNA, RNA, and protein production, especially in rapidly dividing cells. The resulting effect reduces inflammation in autoimmune disorders and limits the proliferation of cancer cells.

The dose of Injexate is individualized and determined by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Healthcare providers calculate the appropriate amount and frequency, and patients should follow the exact regimen prescribed without deviation.

Injexate (methotrexate) is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause severe birth defects and fetal loss. It is also not recommended while breastfeeding, as it may be excreted in breast milk and harm the infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after discontinuation.

To order Injexate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

The primary alternatives to methotrexate are biologic disease‑modifying antirheumatic drugs (DMARDs) such as TNF‑α inhibitors. While biologics target specific cytokines and often have rapid symptom relief, methotrexate offers a broad immunosuppressive effect at a lower cost and with extensive long‑term safety data. Choice of therapy depends on disease severity, patient comorbidities, and response to prior treatments.

Injexate must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If a temporary temperature excursion occurs, discard the product according to local regulations. Always handle the medication using aseptic technique to maintain sterility.

Injexate is supplied for parenteral use and can be given either intravenously or subcutaneously by a qualified healthcare professional. The injection is typically performed in a clinical setting using sterile technique. The exact administration route, volume, and infusion rate are determined by the prescriber based on the therapeutic indication and patient factors.

The most serious adverse events associated with Injexate include bone marrow suppression leading to anemia, leukopenia, or thrombocytopenia; severe liver toxicity such as hepatitis or fibrosis; pulmonary complications like interstitial pneumonitis or fibrosis; and renal impairment that can increase drug accumulation. Patients should be monitored regularly with blood tests and clinical assessments to detect these risks early.

Injexate is contraindicated in pregnant or breastfeeding individuals, patients with known hypersensitivity to methotrexate, and those with severe hepatic or renal impairment. It should also be avoided in patients with active, uncontrolled infections or significant bone marrow disease. Clinicians must evaluate each patient’s medical history before initiating therapy.